Trending Across touchONCOLOGY

At a glance: education, conference reports and articles

CME & Education

Haematological Malignancies
touchTALKS
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Dr Alessandra Tedeschi Watch Time: 39 Minutes

Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.

Learning objectives
Learning Objectives
  • Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
  • Summarize the adverse events associated with second-generation BTK inhibitors
  • Review current management recommendations for people with Waldenström’s macroglobulinaemia
View All

Conference Hub

Haematology
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study

touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis.   Questions: What are the major therapeutic […]

View All

Learning Zone

Ovarian Cancer
touchINSIGHT
Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer
Watch Time: 10 mins

Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.

View All

Journals

Gastrointestinal Oncology
Development of HER2-targeted Therapies for Gastrointestinal Cancer
Kentaro Sawada, Yoshiaki Nakamura, Kohei Shitara

European Oncology & Haematology. 2020;16(1):29-38

Human epidermal growth factor receptor 2 (HER2) is encoded by a proto-oncogene with important roles in the promotion of cell proliferation, differentiation and angiogenesis via the activation of Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) downstream signalling after it forms homodimers or heterodimers with other HER family members.1–2 HER2 overexpression, […]

View All

More From CME & Education

View All

Learn more from touchONCOLOGY with CME-accredited and independent learning activities

Gastrointestinal Oncology
CME ACCREDITED
touchEXPERT OPINIONS
Aiming for new targets in biliary tract cancer
Prof. Do-Youn Oh, Prof. Juan Valle, Dr Rachna Schroff Watch Time: 29 mins

Watch leading experts in biliary tract cancer discuss the current unmet needs and how targeted treatments can improve patient outcomes.

Learning objectives
Learning Objectives
  • Describe the unmet therapeutic needs for patients with biliary tract cancer
  • Describe the genetic characteristics and tumour microenvironment of biliary tract cancers
  • Explain the supporting data for new and emerging treatments for biliary tract cancers
Haematological Malignancies
touchTALKS
Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?
Dr Alessandra Tedeschi Watch Time: 39 Minutes

Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.

Learning objectives
Learning Objectives
  • Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
  • Summarize the adverse events associated with second-generation BTK inhibitors
  • Review current management recommendations for people with Waldenström’s macroglobulinaemia

    • More From The Conference Hub

    View All

    View highlights and coverage from leading international Oncology congresses

    More From Learning Zone

    View All

    Medical education and communication on key topics in the area of Oncology. Content in this section is sponsored by the pharmaceutical industry.

    Renal Cancer
    touchINSIGHT
    First-line Treatment Options for Renal Cell Carcinoma
    Dr Ulka Vaishampayan Watch Time: 10 mins

    Dr Ulka Vaishampayan, from Karmanos Cancer Institute, Wayne State University, MI, USA, discusses first-line treatment options for renal cell carcinoma, including the promising findings from the PROCLAIM registry, which suggest that high dose interleukin-2 is safe and effective before targeted therapy and immune checkpoint blockade.

    Immunotherapy
    touchINSIGHT
    Realising the Promise of Cell Therapy – The Automated In-house CAR T cell Manufacturing System
    Watch Time: 10 Mins

    Chimeric antigen receptor T cells are providing us with a new option for the treatment of B cell malignancies that are non-responsive to standard therapies. Trial results and the potential of this new technology to treat a wider range of cancers are discussed in this Insight.

    Latest Journal Articles

    View All

    Read the latest articles from our peer reviewed Oncology journals published by touchONCOLOGY

    FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020

    European Oncology & Haematology. 2020;16(1):11

    Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]

    Prostate Cancer
    Immunotherapy in Advanced Prostate Cancer
    Manreet Randhawa, Robert Jones

    European Oncology & Haematology. 2020;16(1):44–50

    Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1 Most recently, immunotherapy, in the form of immune checkpoint inhibitors, has been successful in the treatment of a variety of advanced common solid tumours, […]

    Lung Cancer
    Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
    Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Arsela Prelaj, Giulia Galli, Giuseppe Viscardi, Benedetta Trevian, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino, Claudia Proto

    European Oncology & Haematology. 2020;16(1):39-43

    Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]

    Lung Cancer
    ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases
    Mihaela Aldea, Benjamin Besse, Lizza EL Hendriks

    European Oncology & Haematology. 2020;16(1):18-21

    At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in all comers.1 The presence of CNS disease is an indicator of poor prognosis in […]

    Want To Know More About Our Journals?

    Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journals we produce.

    The European Oncology & Haematology and Oncology & Hematology Review (US) are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting.

    Learn more about our journals

    Society & Congress Partners

    View All

    touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar